Literature DB >> 10938027

Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time.

J C Souto1, L Almasy, E Muñiz-Diaz, J M Soria, M Borrell, L Bayén, J Mateo, P Madoz, W Stone, J Blangero, J Fontcuberta.   

Abstract

Lower levels of factor VIII and von Willebrand factor (vWF) have been reported in individuals with blood type O compared with individuals with other ABO blood types. However, this relationship has been demonstrated only by association studies and not by linkage studies. Also, it is not clear whether the ABO locus exerts a functional effect directly on these plasma factors or whether the ABO locus is in linkage disequilibrium with another locus that controls these factors. To distinguish between these 2 possibilities, we applied new statistical methods combining linkage and association tests in a pedigree-based sample. In contrast to most previous studies that used the ABO phenotypes, our study used the ABO genotypes, permitting us to distinguish AO from AA and BO from BB. Our results clearly showed significant linkage between the ABO locus and vWF antigen (P=0.00075). In addition, factor VIII coagulant activity and activated partial thromboplastin time showed suggestive linkage with the ABO locus (P=0.10 and P=0.13). All 3 plasma phenotypes showed significant differences between OO and non-OO genotypes. In addition, vWF antigen exhibited significant differences between O heterozygotes and non-OO homozygotes. This study is unique because it used a combined linkage and association test, which indicated that the ABO locus itself has a functional effect on these plasma phenotypes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10938027     DOI: 10.1161/01.atv.20.8.2024

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  40 in total

1.  The "normal" factor VIII concentration in plasma.

Authors:  Saulius Butenas; Behnaz Parhami-Seren; Anetta Undas; David N Fass; Kenneth G Mann
Journal:  Thromb Res       Date:  2010-05-07       Impact factor: 3.944

2.  Genetic associations for activated partial thromboplastin time and prothrombin time, their gene expression profiles, and risk of coronary artery disease.

Authors:  Weihong Tang; Christine Schwienbacher; Lorna M Lopez; Yoav Ben-Shlomo; Tiphaine Oudot-Mellakh; Andrew D Johnson; Nilesh J Samani; Saonli Basu; Martin Gögele; Gail Davies; Gordon D O Lowe; David-Alexandre Tregouet; Adrian Tan; James S Pankow; Albert Tenesa; Daniel Levy; Claudia B Volpato; Ann Rumley; Alan J Gow; Cosetta Minelli; John W G Yarnell; David J Porteous; John M Starr; John Gallacher; Eric Boerwinkle; Peter M Visscher; Peter P Pramstaller; Mary Cushman; Valur Emilsson; Andrew S Plump; Nena Matijevic; Pierre-Emmanuel Morange; Ian J Deary; Andrew A Hicks; Aaron R Folsom
Journal:  Am J Hum Genet       Date:  2012-06-14       Impact factor: 11.025

3.  ABO blood group is associated with peripheral arterial disease in African Americans: The Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Mindy M Pike; Nicholas B Larson; Christina L Wassel; Kevin P Cohoon; Michael Y Tsai; James S Pankow; Naomi Q Hanson; Paul A Decker; Cecilia Berardi; Kristine S Alexander; Mary Cushman; Neil A Zakai; Suzette J Bielinski
Journal:  Thromb Res       Date:  2017-02-24       Impact factor: 3.944

4.  A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels.

Authors:  Kevin R Viel; Deepa K Machiah; Diane M Warren; Manana Khachidze; Alfonso Buil; Karl Fernstrom; Juan C Souto; Juan M Peralta; Todd Smith; John Blangero; Sandra Porter; Stephen T Warren; Jordi Fontcuberta; Jose M Soria; W Dana Flanders; Laura Almasy; Tom E Howard
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

5.  Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasma.

Authors:  Giancarlo Maria Liumbruno; Maria Laura Sodini; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2008-01       Impact factor: 3.443

6.  Genome-wide studies of von Willebrand factor propeptide identify loci contributing to variation in propeptide levels and von Willebrand factor clearance.

Authors:  A B Ozel; B McGee; D Siemieniak; P M Jacobi; S L Haberichter; L C Brody; J L Mills; A M Molloy; D Ginsburg; J Z Li; K C Desch
Journal:  J Thromb Haemost       Date:  2016-08-19       Impact factor: 5.824

Review 7.  Laboratory testing for von Willebrand disease: toward a mechanism-based classification.

Authors:  Richard Torres; Yuri Fedoriw
Journal:  Clin Lab Med       Date:  2009-06       Impact factor: 1.935

8.  A gene-centric association scan for Coagulation Factor VII levels in European and African Americans: the Candidate Gene Association Resource (CARe) Consortium.

Authors:  Kira C Taylor; Leslie A Lange; Delilah Zabaneh; Ethan Lange; Brendan J Keating; Weihong Tang; Nicholas L Smith; Joseph A Delaney; Meena Kumari; Aroon Hingorani; Kari E North; Mika Kivimaki; Russell P Tracy; Christopher J O'Donnell; Aaron R Folsom; David Green; Steve E Humphries; Alexander P Reiner
Journal:  Hum Mol Genet       Date:  2011-06-15       Impact factor: 6.150

9.  ABO blood group influences transfusion and survival after cardiac surgery.

Authors:  Ian J Welsby; Barbara Phillips-Bute; Joseph P Mathew; Mark F Newman; Richard Becker; Sunil Rao; Carmelo A Milano; Mark Stafford-Smith
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

10.  Comparison of coagulation factors and blood loss between O and non-O blood types following hydroxyethyl starch infusion.

Authors:  Soo Joo Choi; Hyun Joo Ahn; Jae Ik Lee
Journal:  Korean J Anesthesiol       Date:  2010-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.